BioSpace News Archive

The patent comprises of a total of ten allowed claims, and is principally directed to a method of treating non-alcoholic steatohepatitis (NASH) with a colostrum-based composition, as developed by Immuron.

The facility will support the company’s thriving West Coast customer base and will help accelerate growth through new regional partnerships.

The study demonstrated that the diagnostic performance characteristics of the AccutasVET Tapeworm fecal test are clinically significant and exceed the diagnostic performance of current practices and currently available in-clinic tapeworm test kits.

The interview can be viewed at: http://ceolive.tv/hemispherx-heb-ramping-up-manufacturing-to-pursue-multi-billion-dollar-immuno-oncology-market/.

The company reported that it has agreed to immediately repay certain obligations related to CareDx’s acquisition of Allenex AB, which eliminates the requirement to issue 1.8 million new shares.

The joint venture follows a strategic collaboration between Helomics and Skyline announced on November 1, 2017 and represents a deeper partnership between the two companies that is expected to provide Skyline with opportunities to generate revenues from additional markets.

3Shape says the lawsuit and infringement claims are completely unfounded and without merit. 3Shape will vigorously defend itself against such claims.

ScandiDos AB and Varian Medical Systems have completed verification and validation of the Delta4 Discover system for use on TrueBeam and Clinac Ix radiotherapy systems [15-November-2017] UPPSALA, Sweden, Nov. 15, 2017 /PRNewswire/ -- ScandiDos AB (NASDAQ OMX First North: SDOS), a global leader in Quality Assurance (QA) and dosimetry for modern radiation thera

Net revenues were SEK 16.1 M (69.5 M).

QIAGEN is launching the QCI enhancements this week at the AMP 2017 Annual Meeting in Salt Lake City, Utah.